Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RICHARD L BEASLEY

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1093785735
CMS profile
322072
Location
RAPID CITY, SD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$2,475.89

81 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,600.89 80
Honoraria $875.00 1

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 2; records 51–81 of 81 matching records. This page contains 31 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RICHARD L BEASLEY

NPI 1093785735 · CMS profile ID 322072

Allopathic & Osteopathic Physicians / Internal Medicine

RAPID CITY, SD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–81 of 81 matching records. This page contains 31 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1093785735?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RICHARD L BEASLEY, NPI 1093785735, CMS profile ID 322072. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–81 of 81 matching records. This page contains 31 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1093785735?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). RICHARD L BEASLEY, NPI 1093785735, CMS profile ID 322072. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–81 of 81 matching records. This page contains 31 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1093785735?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
RICHARD L BEASLEY, NPI 1093785735, CMS profile ID 322072, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–81 of 81 matching records. This page contains 31 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1093785735?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

81 matching records · $2,475.89 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 81 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–81 of 81.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Boehringer Ingelheim Pharmaceuticals, Inc. $12.4105/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887773991 CMS
GlaxoSmithKline, LLC. $12.9304/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945042463 CMS
Lilly USA, LLC $17.3704/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918276885 CMS
ABBVIE INC. $21.1504/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890580135 CMS
Novo Nordisk Inc $11.3404/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898645325 CMS
Novo Nordisk Inc $0.9904/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899167427 CMS
PFIZER INC. $12.9204/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949100227 CMS
AstraZeneca Pharmaceuticals LP $125.1904/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920258793 CMS
ABBVIE INC. $14.8103/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890580133 CMS
Alkermes, Inc. $16.6003/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 925811743 CMS
GlaxoSmithKline, LLC. $12.0903/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945042465 CMS
E.R. Squibb & Sons, L.L.C. $15.7003/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932722369 CMS
Lilly USA, LLC $10.8202/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918205815 CMS
GlaxoSmithKline, LLC. $21.2802/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945042467 CMS
Janssen Pharmaceuticals, Inc $14.0602/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886883787 CMS
Horizon Therapeutics plc $11.9602/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937591887 CMS
Lilly USA, LLC $15.1202/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918263477 CMS
Astellas Pharma US Inc $12.6402/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940124429 CMS
E.R. Squibb & Sons, L.L.C. $12.0302/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932722365 CMS
Novo Nordisk Inc $1.0102/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899264825 CMS
Novo Nordisk Inc $13.7502/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899324913 CMS
Seqirus USA Inc $875.0002/07/2022 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 900647963 CMS
Horizon Therapeutics plc $12.8902/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937591885 CMS
GlaxoSmithKline, LLC. $13.3402/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945042461 CMS
EISAI INC. $15.0202/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908080293 CMS
AstraZeneca Pharmaceuticals LP $26.8601/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920225971 CMS
Daiichi Sankyo Inc. $15.1701/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930798055 CMS
ABBVIE INC. $20.6101/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890580131 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $12.7701/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887393325 CMS
Novo Nordisk Inc $1.1801/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898686257 CMS
Novo Nordisk Inc $10.5501/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899167935 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,719.77 181
PY2020 $8,248.98 90
PY2021 $1,740.12 97
PY2022 $2,475.89 81
PY2023 $6,311.88 84
PY2024 $1,086.88 39
PY2025 $772.04 26

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $980,740.95 125
PY2024 Recipient $251.75 1
PY2024 Principal investigator $882,135.22 130
PY2023 Recipient $2,715.67 13
PY2023 Principal investigator $328,400.22 85
PY2022 Recipient $3,725.00 1
PY2022 Principal investigator $343,006.38 95
PY2021 Principal investigator $349,179.71 107
PY2020 Principal investigator $578,015.10 168
PY2019 Principal investigator $1,102,184.86 180

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

125 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,529.40 12/31/2025 Non-covered Recipient Entity
RLB MD PC
A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe alopecia areata No dispute reported 06/30/2026 1202534663
Principal investigator 1 Janssen Research & Development, LLC $8,169.00 12/25/2025 Non-covered Recipient Entity
RLB MD PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175390790
Principal investigator 1 Janssen Research & Development, LLC $1,474.00 12/25/2025 Non-covered Recipient Entity
RLB MD PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175390805
Principal investigator 1 SANOFI US SERVICES INC. $13,662.00 12/22/2025 Non-covered Recipient Entity
Rlb MD PC
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226134991
Principal investigator 1 SANOFI US SERVICES INC. $9,574.00 12/22/2025 Non-covered Recipient Entity
Rlb MD PC
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226134995
Principal investigator 1 Janssen Research & Development, LLC $3,748.00 12/19/2025 Non-covered Recipient Entity
RLB MD PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175390821
Principal investigator 1 Janssen Research & Development, LLC $5,828.00 12/15/2025 Non-covered Recipient Entity
RLB MD PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175390786
Principal investigator 1 GENZYME CORPORATION $9,497.18 12/08/2025 Non-covered Recipient Entity
Javara Inc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226110297
Principal investigator 1 SANOFI US SERVICES INC. $1,056.60 12/08/2025 Non-covered Recipient Entity
Rlb MD PC
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226134987
Principal investigator 1 ABBVIE INC. $2,324.30 12/04/2025 Non-covered Recipient Entity
RLB MD PC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202527016
Principal investigator 1 ABBVIE INC. $16,928.16 12/04/2025 Non-covered Recipient Entity
RLB MD PC
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202527024
Principal investigator 1 ABBVIE INC. $2,144.40 12/04/2025 Non-covered Recipient Entity
RLB MD PC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202527032
Principal investigator 1 ABBVIE INC. $11,829.00 12/04/2025 Non-covered Recipient Entity
RLB MD PC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202527040
Principal investigator 1 Janssen Research & Development, LLC $20,700.00 12/01/2025 Non-covered Recipient Entity
RLB MD PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175390697
Principal investigator 1 Janssen Research & Development, LLC $1,474.00 12/01/2025 Non-covered Recipient Entity
RLB MD PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175390798
Principal investigator 1 SANOFI US SERVICES INC. $5,505.00 11/17/2025 Non-covered Recipient Entity
Rlb MD PC
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226134983
Principal investigator 1 SANOFI US SERVICES INC. $1,945.00 11/10/2025 Non-covered Recipient Entity
Rlb MD PC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226134977
Principal investigator 1 SANOFI US SERVICES INC. $5,225.40 11/10/2025 Non-covered Recipient Entity
Rlb MD PC
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226134981
Principal investigator 1 ABBVIE INC. $17,981.64 11/05/2025 Non-covered Recipient Entity
RLB MD PC
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202521927
Principal investigator 1 ABBVIE INC. $4,288.80 11/05/2025 Non-covered Recipient Entity
RLB MD PC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202521929
Principal investigator 1 ABBVIE INC. $8,496.30 11/05/2025 Non-covered Recipient Entity
RLB MD PC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202521931
Principal investigator 1 Janssen Research & Development, LLC $4,422.00 11/03/2025 Non-covered Recipient Entity
RLB MD PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175390774
Principal investigator 1 Ionis Pharmaceuticals, Inc. $2,658.60 10/31/2025 Non-covered Recipient Entity
RLB MD PC DBA HEALTH CONCEPTS
IS354CS15 No dispute reported 06/30/2026 1246789869
Principal investigator 1 Janssen Research & Development, LLC $1,874.00 10/31/2025 Non-covered Recipient Entity
RLB MD PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175390758
Principal investigator 1 SANOFI US SERVICES INC. $21,808.00 10/27/2025 Non-covered Recipient Entity
Rlb MD PC
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226134974
Principal investigator 1 Ionis Pharmaceuticals, Inc. $300.00 10/24/2025 Non-covered Recipient Entity
RLB MD PC DBA HEALTH CONCEPTS
IS354CS5 No dispute reported 06/30/2026 1246789584
Principal investigator 1 Janssen Research & Development, LLC $14,465.00 10/24/2025 Non-covered Recipient Entity
RLB MD PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175390734
Principal investigator 1 SANOFI US SERVICES INC. $2,465.00 10/14/2025 Non-covered Recipient Entity
Rlb MD PC
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226134970
Principal investigator 1 ABBVIE INC. $7,954.20 10/09/2025 Non-covered Recipient Entity
RLB MD PC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202514879
Principal investigator 1 Ionis Pharmaceuticals, Inc. $680.00 10/08/2025 Non-covered Recipient Entity
RLB MD PC DBA HEALTH CONCEPTS
IS354CS9 No dispute reported 06/30/2026 1246788318
Principal investigator 1 Ionis Pharmaceuticals, Inc. $1,275.00 10/08/2025 Non-covered Recipient Entity
RLB MD PC DBA HEALTH CONCEPTS
IS354CS9 No dispute reported 06/30/2026 1246788321
Principal investigator 1 Ionis Pharmaceuticals, Inc. $3,602.80 10/08/2025 Non-covered Recipient Entity
RLB MD PC DBA HEALTH CONCEPTS
IS354CS9 No dispute reported 06/30/2026 1246788326
Principal investigator 1 SANOFI US SERVICES INC. $1,056.60 10/06/2025 Non-covered Recipient Entity
Rlb MD PC
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226134965
Principal investigator 1 Janssen Research & Development, LLC $1,474.00 09/29/2025 Non-covered Recipient Entity
RLB MD PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175390685
Principal investigator 1 Janssen Research & Development, LLC $7,033.00 09/29/2025 Non-covered Recipient Entity
RLB MD PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175390716
Principal investigator 1 Janssen Research & Development, LLC $1,874.00 09/29/2025 Non-covered Recipient Entity
RLB MD PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175390781
Principal investigator 1 SANOFI US SERVICES INC. $7,350.00 09/15/2025 Non-covered Recipient Entity
Rlb MD PC
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226134958
Principal investigator 1 SANOFI US SERVICES INC. $14,132.00 09/15/2025 Non-covered Recipient Entity
Rlb MD PC
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226134962
Principal investigator 1 Janssen Research & Development, LLC $32,718.00 09/08/2025 Non-covered Recipient Entity
RLB MD PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175390746
Principal investigator 1 ABBVIE INC. $4,196.40 09/04/2025 Non-covered Recipient Entity
RLB MD PC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202508766
Principal investigator 1 ABBVIE INC. $12,241.32 09/04/2025 Non-covered Recipient Entity
RLB MD PC
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202508768
Principal investigator 1 ABBVIE INC. $4,688.80 09/04/2025 Non-covered Recipient Entity
RLB MD PC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202508908
Principal investigator 1 Janssen Research & Development, LLC $1,874.00 09/04/2025 Non-covered Recipient Entity
RLB MD PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175390728
Principal investigator 1 SANOFI US SERVICES INC. $1,215.00 09/03/2025 Non-covered Recipient Entity
Rlb MD PC
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226134954
Principal investigator 1 Janssen Research & Development, LLC $1,474.00 08/25/2025 Non-covered Recipient Entity
RLB MD PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175390769
Principal investigator 1 SANOFI US SERVICES INC. $12,483.00 08/18/2025 Non-covered Recipient Entity
Rlb MD PC
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226134946
Principal investigator 1 SANOFI US SERVICES INC. $5,625.00 08/11/2025 Non-covered Recipient Entity
Rlb MD PC
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226134943
Principal investigator 1 ABBVIE INC. $7,020.60 08/06/2025 Non-covered Recipient Entity
RLB MD PC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202502709
Principal investigator 1 ABBVIE INC. $8,615.90 08/06/2025 Non-covered Recipient Entity
RLB MD PC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202502711
Principal investigator 1 ABBVIE INC. $9,627.00 08/06/2025 Non-covered Recipient Entity
RLB MD PC
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202502713
Principal investigator 1 Ionis Pharmaceuticals, Inc. $3,288.60 08/06/2025 Non-covered Recipient Entity
RLB MD PC DBA HEALTH CONCEPTS
IS354CS15 No dispute reported 06/30/2026 1246786113
Principal investigator 1 Janssen Research & Development, LLC $10,750.00 08/04/2025 Non-covered Recipient Entity
RLB MD PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175390704
Principal investigator 1 Janssen Research & Development, LLC $8,968.00 08/01/2025 Non-covered Recipient Entity
RLB MD PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175390649
Principal investigator 1 Janssen Research & Development, LLC $39,278.00 07/28/2025 Non-covered Recipient Entity
RLB MD PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175390740
Principal investigator 1 Janssen Research & Development, LLC $1,474.00 07/28/2025 Non-covered Recipient Entity
RLB MD PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175390752
Principal investigator 1 Ionis Pharmaceuticals, Inc. $6,311.00 07/18/2025 Non-covered Recipient Entity
RLB MD PC DBA HEALTH CONCEPTS
IS354CS9 No dispute reported 06/30/2026 1246785437
Principal investigator 1 GENZYME CORPORATION $1,200.00 07/14/2025 Non-covered Recipient Entity
Rlb MD PC
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226134933
Principal investigator 1 SANOFI US SERVICES INC. $510.00 07/14/2025 Non-covered Recipient Entity
Rlb MD PC
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226134905
Principal investigator 1 SANOFI US SERVICES INC. $21,001.00 07/14/2025 Non-covered Recipient Entity
Rlb MD PC
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226134913
Principal investigator 1 SANOFI US SERVICES INC. $4,465.00 07/14/2025 Non-covered Recipient Entity
Rlb MD PC
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226134921
Principal investigator 1 SANOFI US SERVICES INC. $3,650.00 07/14/2025 Non-covered Recipient Entity
Rlb MD PC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226134939
Principal investigator 1 ABBVIE INC. $2,055.96 07/08/2025 Non-covered Recipient Entity
RLB MD PC
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202497072
Principal investigator 1 ABBVIE INC. $6,291.60 07/08/2025 Non-covered Recipient Entity
RLB MD PC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202497074
Principal investigator 1 GENZYME CORPORATION $2,376.00 07/07/2025 Non-covered Recipient Entity
Rlb MD PC
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226134924
Principal investigator 1 GENZYME CORPORATION $1,200.00 07/07/2025 Non-covered Recipient Entity
Rlb MD PC
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226134929
Principal investigator 1 SANOFI US SERVICES INC. $5,077.80 07/07/2025 Non-covered Recipient Entity
Rlb MD PC
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226134909
Principal investigator 1 ABBVIE INC. $2,461.20 07/02/2025 Non-covered Recipient Entity
RLB MD PC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202494489
Principal investigator 1 ABBVIE INC. $7,000.00 07/01/2025 Non-covered Recipient Entity
RLB MD PC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202493749
Principal investigator 1 Janssen Research & Development, LLC $2,242.00 06/27/2025 Non-covered Recipient Entity
RLB MD PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175390691
Principal investigator 1 Amgen Inc. $5,370.00 06/26/2025 Non-covered Recipient Entity
RLB MD PC DBA HEALTH CONCEPTS
A Phase 3, Multicenter, Randomized, Open-label, Performance Study With Self-administered Subcutaneous Rocatinlimab (AMG 451) in Adolescent and Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Outpost) No dispute reported 06/30/2026 1246647350
Principal investigator 1 Janssen Research & Development, LLC $2,948.00 06/26/2025 Non-covered Recipient Entity
RLB MD PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175390643
Principal investigator 1 SANOFI US SERVICES INC. $14,450.00 06/23/2025 Non-covered Recipient Entity
Rlb MD PC
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226134917
Principal investigator 1 SANOFI US SERVICES INC. $7,450.00 06/16/2025 Non-covered Recipient Entity
Rlb MD PC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 1226134874
Principal investigator 1 SANOFI US SERVICES INC. $20,027.00 06/16/2025 Non-covered Recipient Entity
Rlb MD PC
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226134879
Principal investigator 1 GlaxoSmithKline, LLC. $2,413.60 06/11/2025 Non-covered Recipient Entity
RLB MD PC
A PHASE I/II OBSERVER-BLIND, RANDOMIZED, MULTI-CENTER TRIAL TO EVALUAT No dispute reported 06/30/2026 1192115635
Principal investigator 1 SANOFI US SERVICES INC. $3,600.90 06/09/2025 Non-covered Recipient Entity
Rlb MD PC
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226134882
Principal investigator 1 Janssen Research & Development, LLC $4,716.00 06/06/2025 Non-covered Recipient Entity
RLB MD PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175390815
Principal investigator 1 ABBVIE INC. $4,688.80 06/03/2025 Non-covered Recipient Entity
RLB MD PC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202488433
Principal investigator 1 ABBVIE INC. $11,597.76 06/03/2025 Non-covered Recipient Entity
RLB MD PC
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202488435
Principal investigator 1 Janssen Research & Development, LLC $5,444.00 05/26/2025 Non-covered Recipient Entity
RLB MD PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175390664
Principal investigator 1 Janssen Research & Development, LLC $2,058.00 05/22/2025 Non-covered Recipient Entity
RLB MD PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175390656
Principal investigator 1 GENZYME CORPORATION $1,288.00 05/19/2025 Non-covered Recipient Entity
Rlb MD PC
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226134898
Principal investigator 1 SANOFI US SERVICES INC. $9,327.10 05/19/2025 Non-covered Recipient Entity
Rlb MD PC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226134893
Principal investigator 1 SANOFI US SERVICES INC. $13,097.00 05/19/2025 Non-covered Recipient Entity
Rlb MD PC
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226134902
Principal investigator 1 ABBVIE INC. $4,526.40 05/07/2025 Non-covered Recipient Entity
RLB MD PC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202483673
Principal investigator 1 ABBVIE INC. $8,358.50 05/07/2025 Non-covered Recipient Entity
RLB MD PC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202483675
Principal investigator 1 SANOFI US SERVICES INC. $7,034.00 05/05/2025 Non-covered Recipient Entity
Rlb MD PC
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226134867
Principal investigator 1 SANOFI US SERVICES INC. $8,203.40 05/05/2025 Non-covered Recipient Entity
Rlb MD PC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226134871
Principal investigator 1 Janssen Research & Development, LLC $5,444.00 04/28/2025 Non-covered Recipient Entity
RLB MD PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175390722
Principal investigator 1 Amgen Inc. $22,110.00 04/24/2025 Non-covered Recipient Entity
RLB MD PC DBA HEALTH CONCEPTS
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246647347
Principal investigator 1 Amgen Inc. $4,475.00 04/24/2025 Non-covered Recipient Entity
RLB MD PC DBA HEALTH CONCEPTS
A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon) No dispute reported 06/30/2026 1246647354
Principal investigator 1 AstraZeneca Pharmaceuticals LP $11,450.00 04/23/2025 Non-covered Recipient Entity
RLB MD PC
Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease COPD No dispute reported 06/30/2026 1185543410
Principal investigator 1 ABBVIE INC. $529.45 04/21/2025 Non-covered Recipient Entity
RLB MD PC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202478207
Principal investigator 1 SANOFI US SERVICES INC. $16,416.00 04/14/2025 Non-covered Recipient Entity
Rlb MD PC
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226134862
Principal investigator 1 SANOFI US SERVICES INC. $7,593.10 04/07/2025 Non-covered Recipient Entity
Rlb MD PC
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226134852
Principal investigator 1 ABBVIE INC. $11,829.00 04/03/2025 Non-covered Recipient Entity
RLB MD PC
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202468741
Principal investigator 1 ABBVIE INC. $6,156.00 04/03/2025 Non-covered Recipient Entity
RLB MD PC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202474146
Principal investigator 1 ABBVIE INC. $3,300.50 04/03/2025 Non-covered Recipient Entity
RLB MD PC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202474153
Principal investigator 1 SANOFI US SERVICES INC. $2,250.00 04/02/2025 Non-covered Recipient Entity
Rlb MD PC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 1226134844
Principal investigator 1 Janssen Research & Development, LLC $4,484.00 03/27/2025 Non-covered Recipient Entity
RLB MD PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175390809
Principal investigator 1 Janssen Research & Development, LLC $4,430.00 03/24/2025 Non-covered Recipient Entity
RLB MD PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175390710
Principal investigator 1 SANOFI US SERVICES INC. $28,658.00 03/24/2025 Non-covered Recipient Entity
Rlb MD PC
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226134831
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $41,095.24 03/14/2025 Non-covered Recipient Entity
Rlb MD PC
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE) No dispute reported 06/30/2026 1235994193
Principal investigator 1 SANOFI US SERVICES INC. $5,188.00 03/10/2025 Non-covered Recipient Entity
Rlb MD PC
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226135002
Principal investigator 1 ABBVIE INC. $15,427.92 03/07/2025 Non-covered Recipient Entity
RLB MD PC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202459854
Principal investigator 1 ABBVIE INC. $3,515.00 03/07/2025 Non-covered Recipient Entity
RLB MD PC
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202459858
Principal investigator 1 SANOFI US SERVICES INC. $12,951.70 03/04/2025 Non-covered Recipient Entity
Rlb MD PC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226134839
Principal investigator 1 Janssen Research & Development, LLC $5,124.00 03/03/2025 Non-covered Recipient Entity
RLB MD PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175390680
Principal investigator 1 Janssen Research & Development, LLC $2,722.00 03/03/2025 Non-covered Recipient Entity
RLB MD PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175390763
Principal investigator 1 GENZYME CORPORATION $1,200.00 02/18/2025 Non-covered Recipient Entity
Rlb MD PC
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226134834
Principal investigator 1 SANOFI US SERVICES INC. $7,404.00 02/18/2025 Non-covered Recipient Entity
Rlb MD PC
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226134999
Principal investigator 1 Eli Lilly and Company $891.84 02/10/2025 Non-covered Recipient Entity
LIGHTSHIP INC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187884574
Principal investigator 1 Janssen Research & Development, LLC $11,340.00 02/07/2025 Non-covered Recipient Entity
RLB MD PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175390674
Principal investigator 1 ABBVIE INC. $16,510.20 02/06/2025 Non-covered Recipient Entity
RLB MD PC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202448002
Principal investigator 1 ABBVIE INC. $3,515.00 02/06/2025 Non-covered Recipient Entity
RLB MD PC
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202448317
Principal investigator 1 SANOFI US SERVICES INC. $12,068.00 02/04/2025 Non-covered Recipient Entity
Rlb MD PC
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226135005
Principal investigator 1 Amgen Inc. $16,470.84 01/27/2025 Non-covered Recipient Entity
HEALTH CONCEPTS
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246642116
Principal investigator 1 Janssen Research & Development, LLC $2,722.00 01/24/2025 Non-covered Recipient Entity
RLB MD PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175390670
Principal investigator 1 SANOFI US SERVICES INC. $7,404.00 01/24/2025 Non-covered Recipient Entity
Rlb MD PC
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226134828
Principal investigator 1 Eli Lilly and Company $1,487.00 01/21/2025 Non-covered Recipient Entity
LIGHTSHIP INC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187884120
Principal investigator 1 SANOFI US SERVICES INC. $29,309.00 01/21/2025 Non-covered Recipient Entity
Rlb MD PC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226134820
Principal investigator 1 SANOFI US SERVICES INC. $22,018.00 01/21/2025 Non-covered Recipient Entity
Rlb MD PC
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226134824
Principal investigator 1 AstraZeneca Pharmaceuticals LP $10,656.90 01/17/2025 Non-covered Recipient Entity
RLB MD PC
A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE) No dispute reported 06/30/2026 1185543412
Principal investigator 1 GENZYME CORPORATION $4,752.00 01/06/2025 Non-covered Recipient Entity
Rlb MD PC
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226134858
Principal investigator 1 ABBVIE INC. $2,061.24 01/02/2025 Non-covered Recipient Entity
RLB MD PC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202434795